- Home
- RGEN vs MRNA Comparison
RGEN vs MRNA Comparison
Compare RGEN & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGEN
- MRNA
- Stock Information
- Founded
- RGEN 1981
- MRNA 2010
- Country
- RGEN United States
- MRNA United States
- Employees
- RGEN N/A
- MRNA N/A
- Industry
- RGEN Medical/Dental Instruments
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RGEN Health Care
- MRNA Health Care
- Exchange
- RGEN Nasdaq
- MRNA Nasdaq
- Market Cap
- RGEN 8.2B
- MRNA 9.2B
- IPO Year
- RGEN N/A
- MRNA 2018
- Fundamental
- Price
- RGEN $142.30
- MRNA $24.36
- Analyst Decision
- RGEN Buy
- MRNA Hold
- Analyst Count
- RGEN 11
- MRNA 15
- Target Price
- RGEN $170.90
- MRNA $36.69
- AVG Volume (30 Days)
- RGEN 1.0M
- MRNA 11.9M
- Earning Date
- RGEN 10-28-2025
- MRNA 11-06-2025
- Dividend Yield
- RGEN N/A
- MRNA N/A
- EPS Growth
- RGEN N/A
- MRNA N/A
- EPS
- RGEN 0.03
- MRNA N/A
- Revenue
- RGEN $707,890,000.00
- MRNA $2,232,000,000.00
- Revenue This Year
- RGEN $17.50
- MRNA N/A
- Revenue Next Year
- RGEN $12.74
- MRNA $10.38
- P/E Ratio
- RGEN $4,625.69
- MRNA N/A
- Revenue Growth
- RGEN 11.74
- MRNA N/A
- 52 Week Low
- RGEN $102.97
- MRNA $23.04
- 52 Week High
- RGEN $182.52
- MRNA $56.70
- Technical
- Relative Strength Index (RSI)
- RGEN 44.45
- MRNA 43.32
- Support Level
- RGEN $144.18
- MRNA $23.48
- Resistance Level
- RGEN $151.25
- MRNA $25.56
- Average True Range (ATR)
- RGEN 6.92
- MRNA 1.46
- MACD
- RGEN -2.45
- MRNA -0.32
- Stochastic Oscillator
- RGEN 9.42
- MRNA 15.89
About RGEN Repligen Corporation
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.